Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare all-cause mortality at Day 14 in
participants receiving cefiderocol with participants receiving the comparator, meropenem, in
adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial
pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by
Gram-negative pathogens.